Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02852967 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
A Phase 2 study, sponsored by Kadmon Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT02852967 is a Phase 2 study that has completed, run by Kadmon Corporation. The registered enrollment target is 110 participants.
The verdict
NCT02852967, a Phase 2 study, has completed, sponsored by Kadmon Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Interventions
- DRUG Placebo
- DRUG Belumosudil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2016-09-14 |
| Est. Completion | 2019-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02852967
The ClinicalTrials.gov registry entry for NCT02852967 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02852967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02852967 about?
NCT02852967 is a clinical study titled "A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis". This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
What is the current status of trial NCT02852967?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2016-09-14. Estimated completion is 2019-02-13.
What interventions are being tested in trial NCT02852967?
The interventions under investigation include: Placebo (DRUG), Belumosudil (DRUG).
Who is sponsoring clinical trial NCT02852967?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.